Bain Capital Public Equity LP Has $1.77 Million Stake in Haleon plc (NYSE:HLN)

Bain Capital Public Equity LP increased its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 20.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 185,282 shares of the company's stock after purchasing an additional 30,818 shares during the quarter. Haleon makes up approximately 1.1% of Bain Capital Public Equity LP's portfolio, making the stock its 27th largest position. Bain Capital Public Equity LP's holdings in Haleon were worth $1,768,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in shares of Haleon by 67.5% during the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock valued at $146,232,000 after acquiring an additional 6,175,835 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Haleon in the fourth quarter valued at about $42,193,000. FMR LLC raised its stake in shares of Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company's stock worth $1,038,217,000 after purchasing an additional 3,909,545 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Haleon during the 4th quarter worth about $39,628,000. Finally, Northern Trust Corp lifted its holdings in shares of Haleon by 27.7% during the 4th quarter. Northern Trust Corp now owns 5,412,542 shares of the company's stock valued at $51,636,000 after buying an additional 1,172,931 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Performance

HLN stock traded up $0.10 during trading on Wednesday, reaching $10.77. 19,358,927 shares of the stock were exchanged, compared to its average volume of 7,636,847. The stock has a 50 day simple moving average of $10.20 and a 200-day simple moving average of $9.83. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $48.57 billion, a P/E ratio of 31.66, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. Haleon plc has a twelve month low of $8.12 and a twelve month high of $10.85.

Haleon (NYSE:HLN - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The business had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, sell-side analysts anticipate that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently announced a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. This is a positive change from Haleon's previous -- dividend of $0.05. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. Haleon's payout ratio is 58.97%.

Analyst Upgrades and Downgrades

HLN has been the topic of several recent research reports. Sanford C. Bernstein lowered shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Barclays reiterated an "overweight" rating on shares of Haleon in a research note on Tuesday. Finally, HSBC restated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.